Reduction in intestinal calcium absorption by hydrochlorothiazide in postmenopausal osteoporosis

K. Sakhaee, M. J. Nicar, K. Glass, J. E. Zerwekh, C. Y. Pak

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

In six women with postmenopausal osteoporosis, most of whom responded to 50 μg/day 25-hydroxyvitamin D (25-OHD) therapy with a rise in intestinal calcium (Ca) absorption, 50 mg/day hydrochlorothiazide (TZ) were added to determine whether the resulting decline in urinary Ca would cause Ca retention in the skeleton. Urinary Ca decreased from 183 ± 48 (SD) mg/day to 142 ± 67 mg/day (P < 0.05) when TZ was added. However, fractional Ca absorption also declined from 0.532 ± 0.077 during 25-OHD treatment to 0.401 ± 0.064 during combined 25-OHD and TZ therapy (P < 0.0025). The above changes were accompanied by a significant decline in urinary cAMP from 4.29 ± 1.64 to 3.19 ± 1.44 μmol/g creatinine (P < 0.05) and in serum 1,25-dihydroxyvitamin D from 41 ± 14 to 22 ± 11 pg/ml (P < 0.01). The results suggest that TZ lowers urinary Ca, suppresses parathyroid function, inhibits 1,25-dihydroxyvitamin D synthesis, and thereby reduces intestinal Ca absorption. Thus, combined 25-OHD and TZ therapy probably does not improve Ca balance.

Original languageEnglish (US)
Pages (from-to)1037-1043
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume59
Issue number6
StatePublished - 1984

Fingerprint

Postmenopausal Osteoporosis
Hydrochlorothiazide
Intestinal Absorption
Calcium
Therapeutics
Skeleton
Creatinine
Serum

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Reduction in intestinal calcium absorption by hydrochlorothiazide in postmenopausal osteoporosis. / Sakhaee, K.; Nicar, M. J.; Glass, K.; Zerwekh, J. E.; Pak, C. Y.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 59, No. 6, 1984, p. 1037-1043.

Research output: Contribution to journalArticle

@article{a5cfe35524384de5adf8721e557359bf,
title = "Reduction in intestinal calcium absorption by hydrochlorothiazide in postmenopausal osteoporosis",
abstract = "In six women with postmenopausal osteoporosis, most of whom responded to 50 μg/day 25-hydroxyvitamin D (25-OHD) therapy with a rise in intestinal calcium (Ca) absorption, 50 mg/day hydrochlorothiazide (TZ) were added to determine whether the resulting decline in urinary Ca would cause Ca retention in the skeleton. Urinary Ca decreased from 183 ± 48 (SD) mg/day to 142 ± 67 mg/day (P < 0.05) when TZ was added. However, fractional Ca absorption also declined from 0.532 ± 0.077 during 25-OHD treatment to 0.401 ± 0.064 during combined 25-OHD and TZ therapy (P < 0.0025). The above changes were accompanied by a significant decline in urinary cAMP from 4.29 ± 1.64 to 3.19 ± 1.44 μmol/g creatinine (P < 0.05) and in serum 1,25-dihydroxyvitamin D from 41 ± 14 to 22 ± 11 pg/ml (P < 0.01). The results suggest that TZ lowers urinary Ca, suppresses parathyroid function, inhibits 1,25-dihydroxyvitamin D synthesis, and thereby reduces intestinal Ca absorption. Thus, combined 25-OHD and TZ therapy probably does not improve Ca balance.",
author = "K. Sakhaee and Nicar, {M. J.} and K. Glass and Zerwekh, {J. E.} and Pak, {C. Y.}",
year = "1984",
language = "English (US)",
volume = "59",
pages = "1037--1043",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "6",

}

TY - JOUR

T1 - Reduction in intestinal calcium absorption by hydrochlorothiazide in postmenopausal osteoporosis

AU - Sakhaee, K.

AU - Nicar, M. J.

AU - Glass, K.

AU - Zerwekh, J. E.

AU - Pak, C. Y.

PY - 1984

Y1 - 1984

N2 - In six women with postmenopausal osteoporosis, most of whom responded to 50 μg/day 25-hydroxyvitamin D (25-OHD) therapy with a rise in intestinal calcium (Ca) absorption, 50 mg/day hydrochlorothiazide (TZ) were added to determine whether the resulting decline in urinary Ca would cause Ca retention in the skeleton. Urinary Ca decreased from 183 ± 48 (SD) mg/day to 142 ± 67 mg/day (P < 0.05) when TZ was added. However, fractional Ca absorption also declined from 0.532 ± 0.077 during 25-OHD treatment to 0.401 ± 0.064 during combined 25-OHD and TZ therapy (P < 0.0025). The above changes were accompanied by a significant decline in urinary cAMP from 4.29 ± 1.64 to 3.19 ± 1.44 μmol/g creatinine (P < 0.05) and in serum 1,25-dihydroxyvitamin D from 41 ± 14 to 22 ± 11 pg/ml (P < 0.01). The results suggest that TZ lowers urinary Ca, suppresses parathyroid function, inhibits 1,25-dihydroxyvitamin D synthesis, and thereby reduces intestinal Ca absorption. Thus, combined 25-OHD and TZ therapy probably does not improve Ca balance.

AB - In six women with postmenopausal osteoporosis, most of whom responded to 50 μg/day 25-hydroxyvitamin D (25-OHD) therapy with a rise in intestinal calcium (Ca) absorption, 50 mg/day hydrochlorothiazide (TZ) were added to determine whether the resulting decline in urinary Ca would cause Ca retention in the skeleton. Urinary Ca decreased from 183 ± 48 (SD) mg/day to 142 ± 67 mg/day (P < 0.05) when TZ was added. However, fractional Ca absorption also declined from 0.532 ± 0.077 during 25-OHD treatment to 0.401 ± 0.064 during combined 25-OHD and TZ therapy (P < 0.0025). The above changes were accompanied by a significant decline in urinary cAMP from 4.29 ± 1.64 to 3.19 ± 1.44 μmol/g creatinine (P < 0.05) and in serum 1,25-dihydroxyvitamin D from 41 ± 14 to 22 ± 11 pg/ml (P < 0.01). The results suggest that TZ lowers urinary Ca, suppresses parathyroid function, inhibits 1,25-dihydroxyvitamin D synthesis, and thereby reduces intestinal Ca absorption. Thus, combined 25-OHD and TZ therapy probably does not improve Ca balance.

UR - http://www.scopus.com/inward/record.url?scp=0021686268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021686268&partnerID=8YFLogxK

M3 - Article

C2 - 6490791

AN - SCOPUS:0021686268

VL - 59

SP - 1037

EP - 1043

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 6

ER -